# Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

> **NCT00386087** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 41 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Enzastaurin Hydrochloride

## Key facts

- **NCT ID:** NCT00386087
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2008-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386087, "Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00386087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*